{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:48:37Z","timestamp":1793213317441,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aggressive natural killer-cell (NK-cell) leukemia (ANKL) is an extremely aggressive malignancy with dismal prognosis and lack of targeted therapies. Here, we elucidate the molecular pathogenesis of ANKL using a combination of genomic and drug sensitivity profiling. We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations in<jats:italic>STAT3<\/jats:italic>(21%) and RAS-MAPK pathway genes (21%) as well as in<jats:italic>DDX3X<\/jats:italic>(29%) and epigenetic modifiers (50%). Additional alterations include JAK-STAT copy gains and tyrosine phosphatase mutations, which we show recurrent also in extranodal NK\/T-cell lymphoma, nasal type (NKTCL) through integration of public genomic data. Drug sensitivity profiling further demonstrates the role of the JAK-STAT pathway in the pathogenesis of NK-cell malignancies, identifying NK cells to be highly sensitive to JAK and BCL2 inhibition compared to other hematopoietic cell lineages. Our results provide insight into ANKL genetics and a framework for application of targeted therapies in NK-cell malignancies.<\/jats:p>","DOI":"10.1038\/s41467-018-03987-2","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T16:21:29Z","timestamp":1523636489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Aggressive natural killer-cell leukemia\u00a0mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target"],"prefix":"10.1038","volume":"9","author":[{"given":"Olli","family":"Dufva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Kankainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1085-6382","authenticated-orcid":false,"given":"Tiina","family":"Kelkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-9611","authenticated-orcid":false,"given":"Nodoka","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady Adnan","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-4750","authenticated-orcid":false,"given":"Samuli","family":"Eldfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Malani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-9892","authenticated-orcid":false,"given":"Emma I","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paavo","family":"Pietarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Saikko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panu E.","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teija","family":"Ojala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas P.","family":"Loughran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4383-0579","authenticated-orcid":false,"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Sung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9769","authenticated-orcid":false,"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"3987_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.leu.2403262","volume":"18","author":"R Suzuki","year":"2004","unstructured":"Suzuki, R. et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 18, 763\u2013770 (2004).","journal-title":"Leukemia"},{"key":"3987_CR2","first-page":"1343","volume":"87","author":"SY Song","year":"2002","unstructured":"Song, S. Y. et al. Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica 87, 1343\u20131345 (2002).","journal-title":"Haematologica"},{"key":"3987_CR3","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","volume":"121","author":"E Tse","year":"2013","unstructured":"Tse, E. & Kwong, Y.-L. How I treat NK\/T-cell lymphomas. Blood 121, 4997\u20135005 (2013).","journal-title":"Blood"},{"key":"3987_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1349-7006.2012.02251.x","volume":"103","author":"F Ishida","year":"2012","unstructured":"Ishida, F. et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 103, 1079\u20131083 (2012).","journal-title":"Cancer Sci."},{"key":"3987_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/gcc.20245","volume":"44","author":"Y Nakashima","year":"2005","unstructured":"Nakashima, Y. et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma\/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk\/T-cell lymphoma, nasal type. Genes Chromosom. Cancer 44, 247\u2013255 (2005).","journal-title":"Genes Chromosom. Cancer"},{"key":"3987_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1097\/PAS.0000000000000634","volume":"40","author":"LM Gao","year":"2016","unstructured":"Gao, L.-M. et al. Clinicopathologic characterization of aggressive natural killer cell leukemia involving different tissue sites. Am. J. Surg. Pathol. 40, 836\u2013846 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"3987_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/modpathol.2017.37","volume":"30","author":"J Gao","year":"2017","unstructured":"Gao, J. et al. EBV-negative aggressive NK-cell leukemia\/lymphoma: a clinical and pathological study from a single institution. Mod. Pathol. 30, 1100\u20131115 (2017).","journal-title":"Mod. Pathol."},{"key":"3987_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/PAS.0000000000000735","volume":"41","author":"A Nicolae","year":"2017","unstructured":"Nicolae, A. et al. EBV-negative aggressive NK-cell leukemia\/lymphoma: clinical, pathologic, and genetic features. Am. J. Surg. Pathol. 41, 67\u201374 (2017).","journal-title":"Am. J. Surg. Pathol."},{"key":"3987_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","volume":"115","author":"Y Huang","year":"2010","unstructured":"Huang, Y. et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type. Blood 115, 1226\u20131237 (2010).","journal-title":"Blood"},{"key":"3987_CR10","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","volume":"118","author":"K Karube","year":"2011","unstructured":"Karube, K. et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 118, 3195\u20133204 (2011).","journal-title":"Blood"},{"key":"3987_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat. Genet. 47, 1061\u20131066 (2015).","journal-title":"Nat. Genet."},{"key":"3987_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7025","volume":"6","author":"C K\u00fc\u00e7\u00fck","year":"2015","unstructured":"K\u00fc\u00e7\u00fck, C. et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells. Nat. Commun. 6, 6025 (2015).","journal-title":"Nat. Commun."},{"key":"3987_CR13","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","volume":"6","author":"S Lee","year":"2015","unstructured":"Lee, S. et al. Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type. Oncotarget 6, 17764\u201317776 (2015).","journal-title":"Oncotarget"},{"key":"3987_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","volume":"2","author":"GC Koo","year":"2012","unstructured":"Koo, G. C. et al. Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma. Cancer Discov. 2, 591\u2013597 (2012).","journal-title":"Cancer Discov."},{"key":"3987_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/leu.2013.157","volume":"28","author":"A Bouchekioua","year":"2013","unstructured":"Bouchekioua, A. et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28, 338\u2013348 (2013).","journal-title":"Leukemia"},{"key":"3987_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415 (2013).","journal-title":"Nature"},{"key":"3987_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"3987_CR18","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HLM Koskela","year":"2012","unstructured":"Koskela, H. L. M. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366, 1905\u20131913 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3987_CR19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","volume":"125","author":"YW Chen","year":"2015","unstructured":"Chen, Y.-W. et al. Receptor-type tyrosine-protein phosphatase \u03ba directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma. Blood 125, 1589\u20131600 (2015).","journal-title":"Blood"},{"key":"3987_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/gcc.22348","volume":"55","author":"A Dobashi","year":"2016","unstructured":"Dobashi, A. et al. Frequent BCOR aberrations in extranodal NK\/T-cell lymphoma, nasal type. Genes Chromosom. Cancer 55, 460\u2013471 (2016).","journal-title":"Genes Chromosom. Cancer"},{"key":"3987_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12602","volume":"7","author":"A Roberti","year":"2016","unstructured":"Roberti, A. et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat. Commun. 7, 12602 (2016).","journal-title":"Nat. Commun."},{"key":"3987_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1084\/jem.20160894","volume":"214","author":"AB Moffitt","year":"2017","unstructured":"Moffitt, A. B. et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J. Exp. Med. 214, 1371\u20131386 (2017).","journal-title":"J. Exp. Med."},{"key":"3987_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronn\u00e9","year":"2012","unstructured":"Couronn\u00e9, L., Bastard, C. & Bernard, O. A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95\u201396 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3987_CR24","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/sj.onc.1205571","volume":"21","author":"T Takakuwa","year":"2002","unstructured":"Takakuwa, T. et al. Frequent mutations of Fas gene in nasal NK\/T cell lymphoma. Oncogene 21, 4702\u20134705 (2002).","journal-title":"Oncogene"},{"key":"3987_CR25","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood-2009-06-222794","volume":"114","author":"Y Yamanaka","year":"2009","unstructured":"Yamanaka, Y. et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma\/leukemia. Blood 114, 3265\u20133275 (2009).","journal-title":"Blood"},{"key":"3987_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/35053086","volume":"409","author":"J Irie-Sasaki","year":"2001","unstructured":"Irie-Sasaki, J. et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349\u2013354 (2001).","journal-title":"Nature"},{"key":"3987_CR27","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1073\/pnas.0611665104","volume":"104","author":"X Zhang","year":"2007","unstructured":"Zhang, X. et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc. Natl Acad. Sci. USA 104, 4060\u20134064 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3987_CR28","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.1182\/blood-2010-10-314286","volume":"117","author":"M Kleppe","year":"2011","unstructured":"Kleppe, M. et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 117, 7090\u20137098 (2011).","journal-title":"Blood"},{"key":"3987_CR29","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/sj.leu.2402239","volume":"15","author":"R Di Noto","year":"2001","unstructured":"Di Noto, R. et al. Characterization of two novel cell lines, DERL-2 (CD56+\/CD3+\/TCR\u03b3\u03b4+) and DERL-7 (CD56+\/CD3-\/TCR\u03b3\u03b4-), derived from a single patient with CD56+ non-Hodgkin's lymphoma. Leukemia 15, 1641\u20131649 (2001).","journal-title":"Leukemia"},{"key":"3987_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0145-2126(03)00254-6","volume":"28","author":"IM Chen","year":"2004","unstructured":"Chen, I.-M. et al. A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization. Leuk. Res. 28, 275\u2013284 (2004).","journal-title":"Leuk. Res."},{"key":"3987_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2249.1999.00836.x","volume":"115","author":"I Tsuge","year":"1999","unstructured":"Tsuge, I. et al. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin. Exp. Immunol. 115, 385\u2013392 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"3987_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/sj.leu.2401769","volume":"14","author":"M Yagita","year":"2000","unstructured":"Yagita, M., Huang, C. L., Umehara, H., Matsuo, Y. & Tabata, R. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14, 922\u201330 (2000).","journal-title":"Leukemia"},{"key":"3987_CR33","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong, J. H., Maki, G. & Klingemann, H. G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8, 652\u2013658 (1994).","journal-title":"Leukemia"},{"key":"3987_CR34","first-page":"406","volume":"24","author":"MJ Robertson","year":"1996","unstructured":"Robertson, M. J. et al. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24, 406\u2013415 (1996).","journal-title":"Exp. Hematol."},{"key":"3987_CR35","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.V92.4.1374.416a33_1374_1383","volume":"92","author":"J Tsuchiyama","year":"1998","unstructured":"Tsuchiyama, J. et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma\/leukemia associated with Epstein-Barr virus infection. Blood 92, 1374\u20131383 (1998).","journal-title":"Blood"},{"key":"3987_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.V97.3.708","volume":"97","author":"H Nagata","year":"2001","unstructured":"Nagata, H. et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T\/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 97, 708\u2013713 (2001).","journal-title":"Blood"},{"key":"3987_CR37","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4049\/jimmunol.134.3.1623","volume":"134","author":"J Yodoi","year":"1985","unstructured":"Yodoi, J. et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134, 1623\u20131630 (1985).","journal-title":"J. Immunol."},{"key":"3987_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010).","journal-title":"Cancer Cell"},{"key":"3987_CR39","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman, C. J. et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).","journal-title":"PLoS ONE"},{"key":"3987_CR40","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1172\/JCI42442","volume":"120","author":"S Marubayashi","year":"2010","unstructured":"Marubayashi, S. et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 120, 3578\u20133593 (2010).","journal-title":"J. Clin. Invest."},{"key":"3987_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"3987_CR42","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. CSBJ 13, 504\u2013513 (2015).","journal-title":"CSBJ"},{"key":"3987_CR43","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez, A. et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120, 3048\u20133057 (2012).","journal-title":"Blood"},{"key":"3987_CR44","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611\u20131618 (2012).","journal-title":"Clin. Cancer Res."},{"key":"3987_CR45","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong, Y.-L. et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129, 2437\u20132442 (2017).","journal-title":"Blood"},{"key":"3987_CR46","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3324\/haematol.2013.085068","volume":"98","author":"L Couronn\u00e9","year":"2013","unstructured":"Couronn\u00e9, L. et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 98, 1748\u20131752 (2013).","journal-title":"Haematologica"},{"key":"3987_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/leu.2010.255","volume":"25","author":"J Iqbal","year":"2010","unstructured":"Iqbal, J. et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 25, 348\u2013358 (2010).","journal-title":"Leukemia"},{"key":"3987_CR48","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"K Sch\u00f6nberg","year":"2015","unstructured":"Sch\u00f6nberg, K. et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 75, 2187\u20132199 (2015).","journal-title":"Cancer Res."},{"key":"3987_CR49","doi-asserted-by":"publisher","first-page":"12480","DOI":"10.1073\/pnas.1516208112","volume":"112","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc. Natl Acad. Sci. 112, 12480\u201312485 (2015).","journal-title":"Proc. Natl Acad. Sci."},{"key":"3987_CR50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149\u20131159 (2010).","journal-title":"Lancet Oncol."},{"key":"3987_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3987_CR52","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"3987_CR53","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/arxiv.org\/abs\/1303.3997 (2013)."},{"key":"3987_CR54","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"3987_CR55","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/bioinformatics\/btt730","volume":"30","author":"H Zhao","year":"2014","unstructured":"Zhao, H. et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics 30, 1006\u20131007 (2014).","journal-title":"Bioinformatics"},{"key":"3987_CR56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"3987_CR57","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"3987_CR58","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucl. Acids Res. 38, e164\u2013e164 (2010).","journal-title":"Nucl. Acids Res."},{"key":"3987_CR59","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucl. Acids Res. 45, D777\u2013D783 (2017).","journal-title":"Nucl. Acids Res."},{"key":"3987_CR60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"3987_CR61","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/nar\/gks743","volume":"40","author":"A Gonzalez-Perez","year":"2012","unstructured":"Gonzalez-Perez, A. & Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucl. Acids Res. 40, e169 (2012).","journal-title":"Nucl. Acids Res."},{"key":"3987_CR62","doi-asserted-by":"publisher","unstructured":"Mayakonda, A. & Koeffler, H. P. Maftools: efficient analysis, visualization and summarization of MAF files from large-scale cohort based cancer studies. Preprint at https:\/\/doi.org\/10.1101\/052662 (2016).","DOI":"10.1101\/052662"},{"key":"3987_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","volume":"5","author":"AB Olshen","year":"2004","unstructured":"Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557\u2013572 (2004).","journal-title":"Biostatistics"},{"key":"3987_CR64","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1101\/gr.210641.116","volume":"26","author":"D Kim","year":"2016","unstructured":"Kim, D., Song, L., Breitwieser, F. P. & Salzberg, S. L. Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res. 26, 1721\u20131729 (2016).","journal-title":"Genome Res."},{"key":"3987_CR65","doi-asserted-by":"crossref","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"3987_CR66","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucl. Acids Res. 41, e108 (2013).","journal-title":"Nucl. Acids Res."},{"key":"3987_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"3987_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"3987_CR69","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416\u20131429 (2013).","journal-title":"Cancer Discov."},{"key":"3987_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03987-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03987-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03987-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:22:23Z","timestamp":1693624943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03987-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["3987"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-03987-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]},"assertion":[{"value":"15 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Labcyte, Inc. and FIMM\/University of Helsinki have a collaboration agreement on the utilization of Labcyte\u2019s acoustic dispensing technologies. S.M. has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb (not related to this study). F.I. has received honoraria from Novartis, Asahi Kasei Pharma, Baxalta, Kyowa Hakko-Kirin, Janssen and served as a consultant or in an advisory role for Celgene and Novartis (not related to this study). M.K. has served as consultant for Medix Biochemica (not related to this study). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1567"}}